Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

The immune response of COVID-19 vaccination was monitored and studied in the context of the previously PICOV study (P2020/424), Nephro- VAC studies (P2020/284 and P2020/312) and Lung-VAC study (P2021/182). The constant emergence of new variants of concern (VOCs), which become increasingly better at escaping infection and vaccine induced immune responses, together with waning immunity over time, warrant additional vaccination rounds. This is especially true in immunocompromised populations.In the current study, we want to continue monitoring SARS-CoV-2 specific immunity over the next two years, encompassing several future vaccination campaigns.

Inclusion Criteria:Being a resident or member of staff in a nursing home and having participated in the previously organized PICOV-VAC study.Being cognitively capable to give consent to participate in the study.Being a healthy adults and having participated in the previous REDU-VAC studyBeing a kidney transplant or dialysis patient and having participated in the previous NEPHRO-VAC studyBeing a lung transplant patient and having participated in the previous LUNG-VAC studyExclusion Criteria:Having insufficient knowledge of the Dutch or French language..Having a previous diagnosis of dementia and/or having a mini-mental state examination (MMSE) score < 18/30.Having veins which are not accessible for simple peripheral blood puncture.